epoetin


Also found in: Dictionary, Thesaurus, Encyclopedia.

epoetin

 [e-po´ĕ-tin]
a form of human erythropoietin produced by recombinant technology and having the same amino acid sequence and mechanism of action as endogenous erythropoietin. Used in treatment of anemia from various causes, including chronic renal failure, zidovudine therapy, and cancer chemotherapy; also used prior to surgery in anemic patients to reduce the need for blood transfusion. Administered intravenously or subcutaneously. It is available in two forms, designated epoetin alfa (the form used in the United States) and epoetin beta (used in various other countries). Called also recombinant human erythropoietin.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

EPO

A gene on chromosome 7q22 that encodes erythropoietin, a secreted, glycosylated cytokine found in the plasma, which regulates red cell production by promoting erythroid differentiation and initiating haemoglobin synthesis. Erythropoietin plays a neuroprotective role in response to brain injury and is antiapoptotic.

Molecular pathology
Genetic variability of EPO has been linked to microvascular complications of diabetes type 2, including diabetic retinopathy, nephropathy leading to end-stage renal disease, and neuropathy
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

epoetin

Human erythopoetin made by genetic engineering for use as a drug to treat severe anaemia Brand names are Eprex and Neorecormon.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
SAN ANTONIO -- Epoetin alfa shows considerable promise for prevention of the cognitive dysfunction associated with adjuvant chemotherapy in breast cancer patients, Dr.
Darbepoetin alfa, marketed as Arandesp, and epoetin alfa, marketed as Epogen o and Procrit, are the ESAs approved in the United States; they are administered as often as one to three times per week.
Despite the use of epoetin alfa, approximately 35% of patients with ESKD have persistent anemia (Deved et al., 2009).
Recombinant erythropoietins developed as biosimilars to Eprex[R] and approved in the European Union for treatment of anaemia in chronic renal failure Product INN Authorised Marketing Authorization Holder Binocrit[R] epoetin alfa 2007 Sandoz GmbH, Germany Epoetin alfa epoetin alfa 2007 Hexal Biotech Hexal[R] Forschungs GmbH, Germany Abseamed[R] epoetin alfa 2007 Medice Arzneimittel Putter GMBH & Co, Germany Retacrit[R] epoetin zeta 2007 HOSPIRA Enterprises, The Netherlands Silapo[R] epoetin zeta 2007 STADA Arzneimittel AG, Germany
Published studies have evaluated dosing patterns, drug costs, dosing ratios between epoetin alfa and darbepoetin alfa, and hematological outcomes of ESAs (Hymes et al., 2007; Rasu, Crawford, Manley, & Balkrishnan, 2008; Raymond et al., 2008; Vekeman et al., 2007).
Amgen retained the exclusive right to promote and sell its brand of Epoetin alfa, EPOGEN, for dialysis use in the United States.
US Food and Drug Administration's (USFDA) Oncologic Drugs Advisory Committee has recommended the approval of Pfizer's biosimilar to Amgen's anemia drug Epogen (epoetin alfa) across all indications, it was reported Friday.
However, limitations exist because the two shorter-acting ESAs (epoetin alfa and darbepoetin alfa) were not originally studied or approved in the U.S.
A recent Australian study comparing injection site pain following sc administration of epoetin beta or darbepoetin alfa found that sc injection of epoetin beta was significantly less painful than darbepoetin alfa and that patients preferred epoetin beta (Roger et al., 2008).
Recombinant human erythropoietin (epoetin alpha or Eprex[R] in Canada) is normally dosed subcutaneously one to three times per week.
HOLZKIRCHEN, Germany -- Sandoz, the generic drug unit of Novartis AG, has received European regulatory approval for a biosimilar epoetin alfa, an anemia drug.
The Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) study found no benefit for early correction of hemoglobin in reducing cardiovascular disease (N.